Publications by authors named "Hermann Blankenbach"

Article Synopsis
  • Integrin-based therapies are important in treating inflammation but their general use is limited due to their role in host defense.
  • The novel monoclonal antibody anti-M7 effectively blocks the pro-inflammatory interaction between the integrin Mac-1 and its ligand CD40L without disrupting other critical integrin functions.
  • Unlike traditional anti-Mac-1 therapies that can worsen conditions like sepsis, anti-M7 offers a specific and protective approach to managing inflammation by selectively reducing leukocyte recruitment.
View Article and Find Full Text PDF

Cell accumulation is a prerequisite for adipose tissue inflammation. The leukocyte integrin Mac-1 (CD11b/CD18, αβ) is a classic adhesion receptor critically regulating inflammatory cell recruitment. Here, we tested the hypothesis that a genetic deficiency and a therapeutic modulation of Mac-1 regulate adipose tissue inflammation in a mouse model of diet-induced obesity (DIO).

View Article and Find Full Text PDF

Rationale: CD40L figures prominently in chronic inflammatory diseases such as atherosclerosis. However, since CD40L potently regulates immune function and hemostasis by interaction with CD40 receptor and the platelet integrin GPIIb/IIIa, its global inhibition compromises host defense and generated thromboembolic complications in clinical trials. We recently reported that CD40L mediates atherogenesis independently of CD40 and proposed Mac-1 as an alternate receptor.

View Article and Find Full Text PDF